November 18, 2020

Pfizer, BioNTech COVID-19 vaccine 95% effective in final analysis, will seek EUA within days

By: Judy Mathias

Editor's Note

Just a week after Pfizer revealed an interim analysis showing its COVID-19 vaccine to be more than 90% effective, the company on November 18 released its final efficacy analysis showing the vaccine is 95% effective, and that it protects older people who are most at risk of dying from COVID-19.

Pfizer and German partner BioNTech say they have reached a safety milestone that will allow them to apply for a Food and Drug Administration (FDA) emergency use authorization (EUA) within days.

Sponsored Message

On November 16, Moderna announced that an interim analysis of its COVID-19 vaccine showed it to be 94.5% effective. The Moderna and Pfizer vaccines are both mRNA based and require two doses.


Sign Up For OR a.m.
Sign up for the free OR a.m. eLetter to get news like this in your inbox every morning!

OR Manager Jobs
Live chat by BoldChat